Vincerx Pharma, Inc. – NASDAQ:VINC
Vincerx Pharma stock price today
Vincerx Pharma stock price monthly change
Vincerx Pharma stock price quarterly change
Vincerx Pharma stock price yearly change
Vincerx Pharma key metrics
Market Cap | 6.42M |
Enterprise value | 11.47M |
P/E | -0.3 |
EV/Sales | N/A |
EV/EBITDA | -0.11 |
Price/Sales | N/A |
Price/Book | 0.41 |
PEG ratio | N/A |
EPS | -1.79 |
Revenue | N/A |
EBITDA | -34.20M |
Income | -38.24M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVincerx Pharma stock price history
Vincerx Pharma stock forecast
Vincerx Pharma financial statements
| Jun 2023 | 0 | -11.15M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.71M | |
| Dec 2023 | 1.31M | -4.95M | -376.71% |
| Mar 2024 | 0 | -12.42M |
| 2027 | 7.55M | -18.10M | -239.75% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 35275000 | 11.13M | 31.58% |
|---|---|---|---|
| Sep 2023 | 26276000 | 10.53M | 40.09% |
| Dec 2023 | 18217000 | 6.99M | 38.4% |
| Mar 2024 | 11083000 | 11.70M | 105.61% |
| Jun 2023 | -12.69M | 14.80M | 93K |
|---|---|---|---|
| Sep 2023 | -6.64M | 15.06M | 0 |
| Dec 2023 | -8.01M | 5.75M | 18K |
| Mar 2024 | -7.73M | 0 | 5K |
Vincerx Pharma alternative data
| Aug 2023 | 41 |
|---|---|
| Sep 2023 | 41 |
| Oct 2023 | 41 |
| Nov 2023 | 41 |
| Dec 2023 | 41 |
| Jan 2024 | 41 |
| Feb 2024 | 41 |
| Mar 2024 | 41 |
| Apr 2024 | 41 |
| May 2024 | 42 |
| Jun 2024 | 42 |
| Jul 2024 | 42 |
Vincerx Pharma other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 71018 | 0 |
| Aug 2023 | 54276 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SEELENBERGER ALEXANDER A. officer: See Remarks | Common Stock | 10,500 | $0.95 | $9,965 | ||
Purchase | THOMAS TOM C officer: See Remarks | Common Stock | 5,000 | $0.95 | $4,750 | ||
Purchase | IZUMI RAQUEL E. director, officer.. | Common Stock | 3,440 | $0.93 | $3,199 | ||
Purchase | HAMDY AHMED MD director, officer.. | Common Stock | 5,400 | $0.96 | $5,168 | ||
Purchase | HAMDY AHMED MD director, officer.. | Common Stock | 16,900 | $0.95 | $15,987 | ||
Purchase | IZUMI RAQUEL E. director, officer.. | Common Stock | 13,036 | $0.9 | $11,732 | ||
Purchase | THOMAS TOM C officer: General Counsel and Ch.. | Common Stock | 7,000 | $0.83 | $5,810 | ||
Purchase | HAMDY AHMED MD director, officer.. | Common Stock | 35,280 | $0.87 | $30,552 | ||
Purchase | IZUMI RAQUEL E. director, officer.. | Common Stock | 28,738 | $0.89 | $25,433 | ||
Purchase | LOWE CHRISTOPHER P. director | Common Stock | 11,600 | $1.65 | $19,140 |
| Insider | Compensation |
|---|---|
| Dr. Raquel E. Izumi Ph.D. (1970) Founder, Pres, Chief Operating Officer, Sec. & Director | $652,840 |
| Dr. Ahmed M. Hamdy M.D. (1965) Founder, Chairman & Chief Executive Officer | $622,050 |
Mr. Alexander A. Seelenberger M.B.A., MBA (1979) Chief Financial Officer | $405,460 |
-
What's the price of Vincerx Pharma stock today?
One share of Vincerx Pharma stock can currently be purchased for approximately $0.04.
-
When is Vincerx Pharma's next earnings date?
Unfortunately, Vincerx Pharma's (VINC) next earnings date is currently unknown.
-
Does Vincerx Pharma pay dividends?
No, Vincerx Pharma does not pay dividends.
-
How much money does Vincerx Pharma make?
Vincerx Pharma has a market capitalization of 6.42M.
-
What is Vincerx Pharma's stock symbol?
Vincerx Pharma, Inc. is traded on the NASDAQ under the ticker symbol "VINC".
-
What is Vincerx Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vincerx Pharma?
Shares of Vincerx Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vincerx Pharma's key executives?
Vincerx Pharma's management team includes the following people:
- Dr. Raquel E. Izumi Ph.D. Founder, Pres, Chief Operating Officer, Sec. & Director(age: 55, pay: $652,840)
- Dr. Ahmed M. Hamdy M.D. Founder, Chairman & Chief Executive Officer(age: 60, pay: $622,050)
- Mr. Alexander A. Seelenberger M.B.A., MBA Chief Financial Officer(age: 46, pay: $405,460)
-
Is Vincerx Pharma founder-led company?
Yes, Vincerx Pharma is a company led by its founders Dr. Raquel E. Izumi Ph.D. and Dr. Ahmed M. Hamdy M.D..
-
How many employees does Vincerx Pharma have?
As Jul 2024, Vincerx Pharma employs 42 workers, which is 2% more then previous quarter.
-
When Vincerx Pharma went public?
Vincerx Pharma, Inc. is publicly traded company for more then 5 years since IPO on 27 May 2020.
-
What is Vincerx Pharma's official website?
The official website for Vincerx Pharma is vincerx.com.
-
Where are Vincerx Pharma's headquarters?
Vincerx Pharma is headquartered at 260 Sheridan Avenue, Palo Alto, CA.
-
How can i contact Vincerx Pharma?
Vincerx Pharma's mailing address is 260 Sheridan Avenue, Palo Alto, CA and company can be reached via phone at +65 08006676.
Vincerx Pharma company profile:
Vincerx Pharma, Inc.
vincerx.comNASDAQ
42
Biotechnology
Healthcare
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Palo Alto, CA 94306
CIK: 0001796129
ISIN: US92731L1061
CUSIP: 92731L106
